Zobrazeno 1 - 10
of 485
pro vyhledávání: ''
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-18 (2021)
Cancer Cell International
Cancer Cell International
Background Additional epidermal growth factor receptor (EGFR) mutations confer the drug resistance to generations of EGFR targeted tyrosine kinase inhibitor (EGFR-TKI), posing a major challenge to developing effective treatment of lung adenocarcinoma
Autor:
Xin-Yuan Wang, Qing-Wei Zhang, Jialin Meng, Jin-Nan Chen, Fangrong Yan, Xiaofan Lu, Yu-Jie Zhou, Xiaobo Li, Qi-Wen Wang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background Due to negative results in clinical trials of postoperative chemoradiation for gastric cancer, at present, there is a tendency to move chemoradiation therapy forward in gastric and gastroesophageal junction (GEJ) adenocarcinoma. Several ra
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-13 (2021)
Cancer Cell International
Cancer Cell International
Background Although immunotherapy for colon cancer has made promising progress, only a few patients currently benefit from it. A recent study revealed that infiltrating immune cells are highly relevant to tumor prognosis and influence the expression
Autor:
Christopher Su, J Christine Ye
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-18 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the horizon for clinical approval with
Autor:
Yinkui Wang, Fei Shan, Zhemin Li, Zining Liu, Xiangji Ying, Jiafu Ji, Yan Zhang, Rulin Miao, Kan Xue, Ziyu Li, Shuangxi Li, Yongning Jia
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-17 (2021)
BMC Gastroenterology
BMC Gastroenterology
Background The prognostic values of preoperative tumor markers (TMs) remain elusive in patients with locally advanced gastric cancer (LAGC) after neoadjuvant chemotherapy treatment (NACT). This study aimed to assess and establish a novel scoring syst
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer
BMC Cancer
Background Immunotherapy is a crucial therapeutic approach in oncology. However, most patients with head and neck squamous cell carcinoma (HNSCC) do not derive benefit from immunotherapy. Vascular endothelial growth factor (VEGF)/VEGF Receptor 2 (VEG
Autor:
Simone Agostini, Roberta Mancuso, Andrea Saul Costa, Franca Rosa Guerini, Fabio Trecate, Rossella Miglioli, Elisabetta Menna, Beatrice Arosio, Mario Clerici, the SA. M. B. A. project
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-11 (2021)
Journal of Translational Medicine
Journal of Translational Medicine
Background Sarcopenia is a loss of muscle mass and strength causing disability, morbidity, and mortality in older adults, which is characterized by alterations of the neuromuscular junctions (NMJs). SNAP-25 is essential for the maintenance of NMJ int
Autor:
Dao-Zhen Jiang, Xiang-min Zheng, Haili Lu, Zha Siluo, Qiang Wang, Wei Zhang, Xinyun Xu, Ming Qiu, Chengxiang Shan
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-15 (2021)
BMC Cancer
BMC Cancer
Background Although various clinical trials and real-life studies have tried to explore the value of nab-paclitaxel mono-chemotherapy for metastatic breast cancer (MBC), the safety and efficacy of nab-paclitaxel remain unclear which need to be system
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-22 (2021)
BMC Cancer
BMC Cancer
Background Bladder cancer (BC) is the ninth most common malignant tumor. We constructed a risk signature using immune-related gene pairs (IRGPs) to predict the prognosis of BC patients. Methods The mRNA transcriptome, simple nucleotide variation and
Autor:
Anqiang Wang, Yu Lin, Haitao Zhao, Hanping Wang, Haohai Zhang, Junyu Long, Mingjun Zheng, Ke Hu, Xinting Sang, Xu Yang, Dongxu Wang
Publikováno v:
BMC Medicine, Vol 19, Iss 1, Pp 1-14 (2021)
BMC Medicine
BMC Medicine
Background Immune checkpoint inhibitor (ICI) therapy elicits durable antitumor responses in patients with many types of cancer. Genomic mutations may be used to predict the clinical benefits of ICI therapy. NOTCH homolog-4 (NOTCH4) is frequently muta